AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20305329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 18520606 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg dose of norfloxacin (test formulation)
Number of subjects: 0
Study 18520606 — intervention group
Group type: COMPARATOR
Intervention: 400 mg dose of norfloxacin (reference formulation)
Number of subjects: 0
Study 15823282 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (10 mg/day)
Number of subjects: 20
Study 15823282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12391117 — intervention group
Group type: COMPARATOR
Intervention: Albuterol (inhaled bronchodilator)
Number of subjects: 15
Study 12391117 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (3-week treatment)
Number of subjects: 15
Study 12391117 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 10529079 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary lacidipine (12 microg, 3 repeated boluses)
Number of subjects: 8
Study 10529079 — intervention group
Group type: COMPARATOR
Intervention: Intracoronary papaverine (10 mg)
Number of subjects: 8
Study 7745509 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic surfactant
Number of subjects: 385
Study 7745509 — intervention group
Group type: COMPARATOR
Intervention: Air placebo
Number of subjects: 385
Study 1971644 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical therapy
Number of subjects: 0
Study 1971644 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologicals
Number of subjects: 0
Study 7437378 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete rest in bed
Number of subjects: 40
Study 7437378 — intervention group
Group type: COMPARATOR
Intervention: Ambulation (allowed to move freely in the ward)
Number of subjects: 40
Study 30117241 — intervention group
Group type: EXPERIMENTAL
Intervention: Teachers encouraging children to obtain glasses
Number of subjects: 882
Study 30117241 — intervention group
Group type: EXPERIMENTAL
Intervention: Teachers supporting children's classroom glasses wear
Number of subjects: 882
Study 30117241 — intervention group
Group type: EXPERIMENTAL
Intervention: Teachers believing glasses harm children's vision
Number of subjects: 882
Study 28707379 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiolite drug-eluting stent (DES)
Number of subjects: 103
Study 27234640 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI plus cetuximab
Number of subjects: 472
Study 27234640 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI plus bevacizumab
Number of subjects: 472
Study 24647459 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate glycemic index energy (MGI) bar (47.3 g CHO)
Number of subjects: 10
Study 24647459 — intervention group
Group type: COMPARATOR
Intervention: Fasting (water)
Number of subjects: 10
Study 22529095 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary nailing
Number of subjects: 24
Study 22529095 — intervention group
Group type: COMPARATOR
Intervention: Locking-plate fixation
Number of subjects: 24
Study 20021294 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal rivastigmine
Number of subjects: 0
Study 20021294 — intervention group
Group type: COMPARATOR
Intervention: Oral rivastigmine
Number of subjects: 0
Study 17666359 — intervention group
Group type: EXPERIMENTAL
Intervention: FK506
Number of subjects: 109
Study 17666359 — intervention group
Group type: COMPARATOR
Intervention: CsA
Number of subjects: 109
Study 15911704 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine 30 mg orally
Number of subjects: 17
Study 15911704 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 12913835 — intervention group
Group type: EXPERIMENTAL
Intervention: High-titer (HT) Edmonston-Zagreb measles vaccine
Number of subjects: 9
Study 12913835 — intervention group
Group type: COMPARATOR
Intervention: Standard-titer (ST) measles vaccine
Number of subjects: 9
Study 10919683 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 250 microg via HFA 134a pMDI
Number of subjects: 380
Study 10919683 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate 250 microg via CFC pMDI
Number of subjects: 380
Study 8820174 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine HCl (16 mg po) administered 30 min before clonidine (2 ug/kg infused over 10 min)
Number of subjects: 15
Study 8820174 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine HCl (16 mg po) administered 30 min before apomorphine (0.5 mg sc)
Number of subjects: 15
Study 8820174 — intervention group
Group type: COMPARATOR
Intervention: Clonidine (2 ug/kg infused over 10 min)
Number of subjects: 15
Study 8820174 — intervention group
Group type: COMPARATOR
Intervention: Apomorphine (0.5 mg sc)
Number of subjects: 15
Study 1445740 — intervention group
Group type: COMPARATOR
Intervention: 12 week chemotherapy regimen
Number of subjects: 114
Study 1445740 — intervention group
Group type: EXPERIMENTAL
Intervention: 36 week chemotherapy regimen
Number of subjects: 114
Study 1445740 — intervention group
Group type: EXPERIMENTAL
Intervention: Amenorrheic patients
Number of subjects: 114
Study 1445740 — intervention group
Group type: COMPARATOR
Intervention: Non-amenorrheic patients
Number of subjects: 114
Study 6538423 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics plus nimesulide 200 mg/d
Number of subjects: 40
Study 6538423 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics
Number of subjects: 40
Study 30638067 — intervention group
Group type: EXPERIMENTAL
Intervention: ECHO-AS cohort
Number of subjects: 854493
Study 30638067 — intervention group
Group type: COMPARATOR
Intervention: no-ECHO cohort
Number of subjects: 854493
Study 29678780 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 107
Study 29678780 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonresponders with nonischemic cardiomyopathy
Number of subjects: 107
Study 27455354 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Quality of Life (QoL) at week 4
Number of subjects: 0
Study 27455354 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal Quality of Life (QoL) at week 4
Number of subjects: 0
Study 27455354 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal Quality of Life (QoL) at week 4 (adjusted for baseline variables)
Number of subjects: 0
Study 25302762 — intervention group
Group type: EXPERIMENTAL
Intervention: Schema-therapy
Number of subjects: 320
Study 25302762 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-as-usual
Number of subjects: 320
Study 25302762 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarification-oriented psychotherapy
Number of subjects: 320
Study 25302762 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with co-occurring depression
Number of subjects: 320
Study 25302762 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline depression
Number of subjects: 320
Study 22550699 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg
Number of subjects: 17802
Study 22550699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17802
Study 20496307 — intervention group
Group type: EXPERIMENTAL
Intervention: Kanamycin POS® eye ointment (5 times a day for 7 days)
Number of subjects: 25
Study 20496307 — intervention group
Group type: COMPARATOR
Intervention: Placebo eye ointment
Number of subjects: 25
Study 18568983 — intervention group
Group type: EXPERIMENTAL
Intervention: Short lag
Number of subjects: 0
Study 18568983 — intervention group
Group type: EXPERIMENTAL
Intervention: Long lag
Number of subjects: 0
Study 18568983 — intervention group
Group type: COMPARATOR
Intervention: Elderly controls
Number of subjects: 0
Study 16098854 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine controlled release (CR) 12.5 mg
Number of subjects: 373
Study 16098854 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine controlled release (CR) 25 mg
Number of subjects: 373
Study 16098854 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 373
Study 11903942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 11903942 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 20 microg x kg(‐1)
Number of subjects: 100
Study 11903942 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 40 microg x kg(‐1)
Number of subjects: 100
Study 11903942 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 80 microg x kg(‐1)
Number of subjects: 100
Study 9685028 — intervention group
Group type: EXPERIMENTAL
Intervention: Nipple cone morphology
Number of subjects: 89
Study 9685028 — intervention group
Group type: EXPERIMENTAL
Intervention: Oval cone morphology
Number of subjects: 89
Study 9685028 — intervention group
Group type: EXPERIMENTAL
Intervention: Aetiological factors
Number of subjects: 89
Study 7972349 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 24
Study 7972349 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.5 mg
Number of subjects: 24
Study 7972349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 2504375 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted diet (avoiding milk and other dairy products, eggs, fish, peanuts, and soybeans) for mothers who breast fed
Number of subjects: 221
Study 2504375 — intervention group
Group type: COMPARATOR
Intervention: Breast feeding without dietary restrictions
Number of subjects: 221
Study 2504375 — intervention group
Group type: COMPARATOR
Intervention: Casein hydrolysate formula for infants not breast fed
Number of subjects: 221
Study 2504375 — intervention group
Group type: COMPARATOR
Intervention: Soy milk formula for infants not breast fed
Number of subjects: 221
Study 2504375 — intervention group
Group type: COMPARATOR
Intervention: Cows' milk formula for infants not breast fed
Number of subjects: 221
Study 1221227 — intervention group
Group type: EXPERIMENTAL
Intervention: s.c. heparin and dextran 40 (small doses)
Number of subjects: 95
Study 31377851 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium diet (LNa, 15 mg kg‐1 day‐1)
Number of subjects: 15
Study 31377851 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual diet (UDiet, 46 (37-56) mg kg‐1 day‐1)
Number of subjects: 15
Study 31377851 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium diet (HNa, 100 mg kg‐1 day‐1)
Number of subjects: 15
Study 31377851 — intervention group
Group type: COMPARATOR
Intervention: Control group (Usual diet)
Number of subjects: 15
Study 30235221 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily self-report questionnaires
Number of subjects: 50
Study 30235221 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily use of PA monitors (Fitbit One™)
Number of subjects: 50
Study 30235221 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention strategies (automated data collection, prorated incentive structure, dedicated study staff, 2-wave process)
Number of subjects: 50
Study 25986296 — intervention group
Group type: COMPARATOR
Intervention: Massage therapy alone
Number of subjects: 40
Study 25986296 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy combined with meditation
Number of subjects: 40
Study 25130518 — intervention group
Group type: EXPERIMENTAL
Intervention: Telecare management intervention
Number of subjects: 405
Study 25130518 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 405
Study 22458699 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm up
Number of subjects: 12
Study 22458699 — intervention group
Group type: COMPARATOR
Intervention: No warm up
Number of subjects: 12
Study 19969618 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-child discussions about sexual topics
Number of subjects: 141
Study 18654785 — intervention group
Group type: EXPERIMENTAL
Intervention: CE‐3D‐tFLASH
Number of subjects: 31
Study 18654785 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG/breath‐gated CE‐3D‐TrueFISP
Number of subjects: 31
Study 18654785 — intervention group
Group type: EXPERIMENTAL
Intervention: CE‐3D‐TrueFISP
Number of subjects: 31
Study 18654785 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D‐TrueFISP
Number of subjects: 31
Study 18654785 — intervention group
Group type: COMPARATOR
Intervention: ECG/breath‐gated 3D‐TrueFISP
Number of subjects: 31
Study 15716214 — intervention group
Group type: EXPERIMENTAL
Intervention: Zaleplon 5 and 10 mg nightly for 6 to 12 months
Number of subjects: 0
Study 15716214 — intervention group
Group type: COMPARATOR
Intervention: Placebo (during the 7-day single-blind placebo-controlled run-out period)
Number of subjects: 0
Study 12353407 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine (40 mL)
Number of subjects: 30
Study 12353407 — intervention group
Group type: COMPARATOR
Intervention: 0.5% ropivacaine (40 mL) plus clonidine (40 micrograms)
Number of subjects: 30
Study 9823343 — intervention group
Group type: EXPERIMENTAL
Intervention: Apraclonidine
Number of subjects: 40
Study 9823343 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine
Number of subjects: 40
Study 7613410 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured assessment schedule taught to practitioners
Number of subjects: 440
Study 7613410 — intervention group
Group type: COMPARATOR
Intervention: Control group (no structured assessment)
Number of subjects: 440
Study 2584544 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured laboratory setting
Number of subjects: 0
Study 2584544 — intervention group
Group type: COMPARATOR
Intervention: Self-directed self-taught modules
Number of subjects: 0
Study 268268 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (vincristine, 6-mercaptopurine, hydroxyurea, prednisone)
Number of subjects: 16
Study 7128841 — intervention group
Group type: EXPERIMENTAL
Intervention: Ortho‐Novum 1/50 tablets
Number of subjects: 0
Study 7128841 — intervention group
Group type: EXPERIMENTAL
Intervention: Ortho‐Novum 1/35 tablets
Number of subjects: 0
Study 7128841 — intervention group
Group type: EXPERIMENTAL
Intervention: Modicon tablets
Number of subjects: 0
Study 7128841 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest dose product (unspecified)
Number of subjects: 0
Study 31389607 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE combined with HIFU
Number of subjects: 100
Study 31389607 — intervention group
Group type: COMPARATOR
Intervention: TACE (Control Group)
Number of subjects: 100
Study 28885402 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA); given within 3 hours after delivery; specific dosage not mentioned.
Number of subjects: 0
Study 28885402 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic TXA; specific dosage and duration not mentioned.
Number of subjects: 0
Study 27969026 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone application (App) for self-care, used for 12 weeks
Number of subjects: 53
Study 27969026 — intervention group
Group type: COMPARATOR
Intervention: No smartphone application (Control group)
Number of subjects: 53
Study 23768250 — intervention group
Group type: EXPERIMENTAL
Intervention: AVN-211 (CD-008-0173)
Number of subjects: 47
Study 23768250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 22739133 — intervention group
Group type: EXPERIMENTAL
Intervention: PrePex (nonsurgical male circumcision)
Number of subjects: 217
Study 22739133 — intervention group
Group type: COMPARATOR
Intervention: Dorsal-slit method (surgical male circumcision)
Number of subjects: 217
Study 19435740 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 125
Study 19435740 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 125
Study 17562974 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 100 mg daily
Number of subjects: 387
Study 17562974 — intervention group
Group type: COMPARATOR
Intervention: Aliskiren 150 mg daily
Number of subjects: 387
Study 17562974 — intervention group
Group type: COMPARATOR
Intervention: Aliskiren 300 mg daily
Number of subjects: 387
Study 15330493 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyben Vital 5 g daily
Number of subjects: 112
Study 15330493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 11931314 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational maskers comprised of narrow-band sequences
Number of subjects: 0
Study 11931314 — intervention group
Group type: COMPARATOR
Intervention: Gaussian noise bursts
Number of subjects: 0
Study 11931314 — intervention group
Group type: COMPARATOR
Intervention: No masker
Number of subjects: 0
Study 9680674 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 7986974 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg/day for one week
Number of subjects: 88
Study 7986974 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg/day for one week followed by clarithromycin 1 g/day for 2 weeks (group B)
Number of subjects: 88
Study 7986974 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg/day for one week followed by tripotassium dicitrato bismuthate 480 mg/day and clarithromycin 1 g/day for two weeks (group C)
Number of subjects: 88
Study 7986974 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripotassium dicitrato bismuthate 480 mg/day and clarithromycin 1 g/day for two weeks (group D)
Number of subjects: 88
Study 2534839 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 5 micrograms/kg
Number of subjects: 60
Study 2534839 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 10 micrograms/kg
Number of subjects: 60
Study 2534839 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl with etomidat
Number of subjects: 60
Study 2534839 — intervention group
Group type: COMPARATOR
Intervention: Control (0.9% saline solution)
Number of subjects: 60
Study 2534839 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentalum with fentanyl
Number of subjects: 60
Study 1091148 — intervention group
Group type: EXPERIMENTAL
Intervention: Human placental lactogen (HPL) treatment group
Number of subjects: 2733
Study 1091148 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2733
Study 31814335 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme Replacement Therapy (ERT) in CLN2 disease patients
Number of subjects: 21
Study 31814335 — intervention group
Group type: COMPARATOR
Intervention: Neurofilament light levels before treatment in CLN2 disease patients
Number of subjects: 21
Study 31814335 — intervention group
Group type: COMPARATOR
Intervention: Neurofilament light levels in TPP1-null dogs
Number of subjects: 21
Study 31814335 — intervention group
Group type: COMPARATOR
Intervention: Neurofilament light levels in control dogs (TPP1+/− and WT)
Number of subjects: 21
Study 28973619 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous oxygen for 72 hours (n=2668)
Number of subjects: 8003
Study 28973619 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal oxygen (21:00 to 07:00 hours) for 3 nights (n=2667)
Number of subjects: 8003
Study 28973619 — intervention group
Group type: COMPARATOR
Intervention: Control (oxygen only if clinically indicated; n=2668)
Number of subjects: 8003
Study 25499589 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone with one set of osmotic dilators plus misoprostol
Number of subjects: 50
Study 25499589 — intervention group
Group type: COMPARATOR
Intervention: Two sets of osmotic dilators plus misoprostol (control group)
Number of subjects: 50
Study 24077199 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic alone
Number of subjects: 120
Study 24077199 — intervention group
Group type: COMPARATOR
Intervention: Local anesthetic with steroids
Number of subjects: 120
Study 20687845 — intervention group
Group type: EXPERIMENTAL
Intervention: CDA lotion (non-irritating hydrating lotion)
Number of subjects: 0
Study 20687845 — intervention group
Group type: EXPERIMENTAL
Intervention: CDA lotion (twice-daily application for 4 days)
Number of subjects: 0
Study 20687845 — intervention group
Group type: EXPERIMENTAL
Intervention: CDA lotion
Number of subjects: 0
Study 20687845 — intervention group
Group type: COMPARATOR
Intervention: Currently available moisturizing products
Number of subjects: 0
Study 19638365 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive statin administration before percutaneous coronary intervention (PCI)
Number of subjects: 50
Study 16762666 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual feedback from load-time histories of their performance compared with a criterion standard
Number of subjects: 40
Study 16762666 — intervention group
Group type: COMPARATOR
Intervention: No feedback
Number of subjects: 40
Study 15210501 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily (OD) gentamicin regimen
Number of subjects: 297
Study 15210501 — intervention group
Group type: COMPARATOR
Intervention: Multi-dose (MD) gentamicin regimen
Number of subjects: 297
Study 15210501 — intervention group
Group type: EXPERIMENTAL
Intervention: Both OD and MD regimens
Number of subjects: 297
Study 10027935 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor
Number of subjects: 9
Study 10027935 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blocker
Number of subjects: 9
Study 10027935 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy volunteers)
Number of subjects: 9
Study 8705090 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled release tablet of 300 mg theophylline
Number of subjects: 7
Study 8705090 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dose equivalent to 131.46 mg theophylline
Number of subjects: 7
Study 1324637 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin (3 mg/kg body weight)
Number of subjects: 12
Study 1324637 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin (1,000 mg)
Number of subjects: 12
Study 6706044 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance
Number of subjects: 266
Study 6706044 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 266
Study 6706044 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma glucose concentration
Number of subjects: 266
Study 6706044 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐h and fasting plasma glucose values
Number of subjects: 266
Study 31152441 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan 50 mg
Number of subjects: 4000
Study 31152441 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan 100 mg
Number of subjects: 4000
Study 31152441 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan 200 mg
Number of subjects: 4000